Table 2.

Proportion of Follow-up Visits with Laboratory Tests Available at Which Elevated Liver Enzyme Tests^* Were Identified, by Disease and Drug Exposure

	RA Patients (n = 1953)		PsA Patients (n = 151)
	Proportion with AST or ALT > 1× ULN, %	Proportion with AST or ALT > 2× ULN, %	Proportion with AST or ALT > 1× ULN, %	Proportion with AST or ALT > 2× ULN, %
Methotrexate alone, %	22	1	35	0
Leflunomide alone, %	17	2	-	-
Methotrexate + leflunomide, %	31	5	-	-
Neither methotrexate nor leflunomide, %	14	2	28	3
P value for column	< 0.01	< 0.01	NS	NS

ULN = upper limit of normal; NS = Not significant; - indicates fewer than 10 PsA patients were on this treatment regimen

^*Defined as AST or ALT greater than 1× or 2× times the upper limit of the laboratory normal (ULN)